Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Adopting a Functional Precision Medicine Approach For Individualized Pediatric Cancer Treatments
Sponsor: First Ascent Biomedical Inc.
A PHASE1 clinical study on Recurrent Childhood Acute Lymphoblastic Leukemia and Recurrent Childhood Acute Myeloid Leukemia, this trial is actively recruiting participants. The trial is conducted by First Ascent Biomedical Inc. and has accumulated 9 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Aug 2025 — Present [monthly]
Recruiting PHASE1
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE1
Phase: None → PHASE1
-
Apr 2025 — Jul 2025 [monthly]
Recruiting
-
Sep 2024 — Apr 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
▶ Show 4 earlier versions
-
Jun 2024 — Jul 2024 [monthly]
Recruiting
-
Mar 2024 — Jun 2024 [monthly]
Recruiting
-
Sep 2023 — Mar 2024 [monthly]
Recruiting
-
Jun 2023 — Sep 2023 [monthly]
Recruiting
First recorded
Feb 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- First Ascent Biomedical Inc.
- Florida International University
- National Institute on Minority Health and Health Disparities (NIMHD)
- Nicklaus Children's Hospital f/k/a Miami Children's Hospital
For direct contact, visit the study record on ClinicalTrials.gov .